~~<i id='1444581740'><strike id='1444581740'><tt id='1444581740'><pre id='1444581740'></pre></tt></strike></i>~~

Home» focus» knowledge

knowledge

author：Wikipedia 2025-10-01 11:50:53 Page View：76

Editor’s note: A recording of the event is embedded below.

After a few go-go years, the early-stage biotech market has cooled considerably. Two VCs will weigh in on what distinguishes great science from bad investments.

Featured Speakers

Irena Melnikova, Ph.D., partner, Pfizer Ventures
Rakhshita Dhar, senior director, venture investments, Leaps by Bayer
Frank S. David, M.D., Ph.D., managing director, Pharmagellan (moderator)

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Burning questions about Delta and the next phase of the Covid pandemic
Next article： Anesthesiologist group: stop taking Ozempic before surgery

knowledge

Bright Health sells Medicare Advantage business to Molina

BrightHealthisofficiallyleavingthehealthinsurancemarket.ThecompanyhasagreedtosellitsMedicareAdvantag

Streamlined flu vaccines recommended by FDA advisory panel

AfluvaccinesyringerestsonatableatavaccinationclinicinLakewood,Calif.MarioTama/GettyImagesWhenAmerica

As demand for Covid shots wanes, Moderna seeks its next success

RubyWallauforSTATModernachairmanNoubarAfeyanexudedstarpowerearlierthismonthashecommandedthespotlight

Why Talkspace is targeting Medicare, a tricky market

AdobeOverthelastfewyears,virtualmentalhealthcompanyTalkspacehasbeenonarelentlessquesttoconquertheins